Ignite Creation Date:
2024-05-06 @ 2:54 AM
Last Modification Date:
2024-10-26 @ 11:25 AM
Study NCT ID:
NCT02151526
Status:
COMPLETED
Last Update Posted:
2022-04-26
First Post:
2014-05-14
Brief Title:
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major Also Referred to as Transfusion-dependent β-Thalassemia TDT and Sickle Cell Disease
Sponsor:
bluebird bio
Organization:
bluebird bio
Organization Data
Organization:
bluebird bio
Class:
INDUSTRY
Study ID:
HGB-205
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
bluebird bio
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None